Overview

Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols

Status:
Unknown status
Trial end date:
2009-09-01
Target enrollment:
0
Participant gender:
All
Summary
The investigators will study 2 doses of etoricoxib to prove that 60 mg once daily will be non-inferior to etoricoxib 90mg daily (for 14 days) in the treatment of acute ankle sprain in sports. The investigators objective is to discuss the point that the investigators will follow the minimal dose that is effective for the treatment of this acute condition in orthopedic.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
NĂșcleo de Estudos em Esportes e Ortopedia, Brazil
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Anti-Inflammatory Agents, Non-Steroidal
Etoricoxib
Criteria
Inclusion Criteria:

- patients that suffered an ankle sprain in the last 12 hours and seek medical
assistance

Exclusion Criteria:

- anterior history of trauma / fractures in the affected ankle

- history of hypertension / gastrointestinal problems

- patients that did not agree to sign the informed consent to participate in the study